Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction
- 10 August 2016
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 72 (11) , 1363-1371
Abstract
Purpose This study aimed to determine possible effects of voriconazole and posaconazole on the pharmacokinetics and pharmacological effects of sublingual buprenorphine. Methods We used a randomized, placebo-controlled crossover study design with 12 healthy male volunteers. Subjects were given a dose of 0.4 mg (0.6 mg during placebo phase) sublingual buprenorphine after a 5-day oral pretreatment with either (i) placebo, (ii) voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter or (iii) posaconazole 400 mg twice daily. Plasma and urine concentrations of buprenorphine and its primary active metabolite norbuprenorphine were monitored over 18 h and pharmacological effects were measured. Results Compared to placebo, voriconazole increased the mean area under the plasma concentration-time curve (AUC0–∞) of buprenorphine 1.80-fold (90 % confidence interval 1.45–2.24; P < 0.001), its peak concentration (Cmax) 1.37-fold (P < 0.013) and half-life (t ½ ) 1.37-fold (P < 0.001). Posaconazole increased the AUC00-∞ of buprenorphine 1.25-fold (P < 0.001). Most of the plasma norbuprenorphine concentrations were below the limit of quantification (0.05 ng/ml). Voriconazole, unlike posaconazole, increased the urinary excretion of norbuprenorphine 1.58-fold (90 % confidence interval 1.18–2.12; P < 0.001) but there was no quantifiable parent buprenorphine in urine. Plasma buprenorphine concentrations correlated with the pharmacological effects, but the effects did not differ significantly between the phases. Conclusions Voriconazole, and to a minor extent posaconazole, increase plasma exposure to sublingual buprenorphine, probably via inhibition of cytochrome P450 3 A and/or P-glycoprotein. Care should be exercised in the combined use of buprenorphine with triazole antimycotics, particularly with voriconazole, because their interaction can be of clinical importance.Keywords
Funding Information
- State Research Funding (13821)
This publication has 61 references indexed in Scilit:
- Buprenorphine Metabolites, Buprenorphine-3-glucuronide and Norbuprenorphine-3-glucuronide, Are Biologically ActiveAnesthesiology, 2011
- Differential Involvement of P-Glycoprotein (ABCB1) in Permeability, Tissue Distribution, and Antinociceptive Activity of Methadone, Buprenorphine, and Diprenorphine: In Vitro and In Vivo EvaluationJournal of Pharmaceutical Sciences, 2009
- Interaction between buprenorphine and atazanavir or atazanavir/ritonavirDrug and Alcohol Dependence, 2007
- Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetic Interaction between Voriconazole and Methadone at Steady State in Patients on Methadone TherapyAntimicrobial Agents and Chemotherapy, 2007
- Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjectsBritish Journal of Clinical Pharmacology, 2007
- BuprenorphineClinical Pharmacokinetics, 2005
- The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug InteractionsDrug Safety, 2005
- Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse historyJournal of Pain and Symptom Management, 2004
- Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomesLife Sciences, 1997